| ￥1800 | |
| Z05025-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
|
| Endotoxin Level | Less than 1EU per μg by the LAL method. | |
| Expression System | E.coli | |
| Theoretical Molecular Weight | 35.9 kDa | |
| Apparent Molecular Weight | The protein has a predicted MW of 35.9 kDa same as Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22 μm filtered solution in 50mM Tris, 240mM NaCl (pH 8.5). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Annexin V/ANXA5, Human is greater than 95% as determined by SEC-HPLC. »
Annexin V/ANXA5, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Propidium iodide (PI) is widely used in conjunction with Annexin V to determine if cells are viable, apoptotic, or necrotic through differences in plasma membrane integrity and permeability. The Annexin V/PI protocol is a commonly used approach for studying apoptotic cells. PI is used more often than other nuclear stains because it is economical, stable and a good indicator of cell viability, based on its capacity to exclude dye in living cells. |
| Synonyms | Annexin A5; Anchorin CII; Annexin V; Annexin-5; Calphobindin I; CBP-I; Endonexin II; PP4; PAP-I; VAC-alpha; ANX5; ENX2; ANXA5; HEL-S-7; RPRGL3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
